MDxHealth SA (NASDAQ:MDXH) Sees Large Decrease in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 17,033 shares, a drop of 24.2% from the February 12th total of 22,470 shares. Based on an average daily trading volume, of 112,233 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the stock are short sold. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 112,233 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently modified their holdings of MDXH. XTX Topco Ltd increased its holdings in shares of MDxHealth by 220.0% in the 4th quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock valued at $146,000 after acquiring an additional 28,090 shares during the last quarter. Millennium Management LLC boosted its stake in MDxHealth by 328.3% in the fourth quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock valued at $417,000 after acquiring an additional 89,553 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of MDxHealth in the 4th quarter worth approximately $68,000. 683 Capital Management LLC acquired a new stake in MDxHealth in the fourth quarter worth $384,000. Finally, Lazard Asset Management LLC acquired a new position in shares of MDxHealth during the fourth quarter valued at $83,000.

Analysts Set New Price Targets

Several research firms have recently issued reports on MDXH. BTIG Research reissued a “buy” rating and set a $7.00 price objective on shares of MDxHealth in a research note on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, MDxHealth has an average rating of “Moderate Buy” and a consensus target price of $7.75.

MDxHealth Price Performance

MDXH stock traded down $0.05 during trading on Friday, reaching $3.20. 48,075 shares of the stock traded hands, compared to its average volume of 105,867. The business’s 50 day moving average price is $3.52 and its 200-day moving average price is $3.78. The firm has a market capitalization of $158.40 million, a PE ratio of -4.78 and a beta of 1.61. MDxHealth has a 52-week low of $1.36 and a 52-week high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Thursday, February 26th. The company reported $999.00 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $999.13. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The business had revenue of $29.55 million for the quarter, compared to analyst estimates of $26.05 million. On average, equities research analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.